TSU: Sanguis Hemostatic gel

2023: Hemostatic Development

According to the World Health Organization, more than 5 million deaths due to injuries are recorded annually in the world, with about 40% of deaths caused by acute blood loss. At the prehospital stage, up to 80% of victims die due to the inability to stop blood in a timely manner. Total blood losses for wounds, injuries, complications of operations can reach 2 liters or more. Stopping bleeding as soon as possible is a priority to save the lives of those affected.

Young researcher Mikhail Kovtunov from Tomsk State University has developed the hemostatic agent Sanguis - a hemostatic gel based on natural polysaccharides, representatives of Mendeleev Venture Investments said on December 13, 2023. Polysaccharides have physicochemical properties that are often used in medicine, the food industry and other fields.

According to the author of the project, Sanguis has special properties: it instantly stops bleeding, effectively clotting blood and forming a protective film on the wound surface. At the same time, the gel is absolutely safe and compatible with living tissues.

The main advantages of Sanguis are ease of use, ergonomics and affordable price. The gel can be used under any conditions, without special preparation. In terms of costs for 1 procedure, Sanguis is 2-7 times cheaper than imported analogues.

According to the developers, the potential audience for their product is tens of millions of patients a year. These are victims of road accidents, at work, military, ambulance and surgery patients. In Russia alone, 8.5 million operations are performed annually, often complicated by bleeding.

Scientists have already conducted successful primary trials of Sanguis and plan to scale production. They expect to occupy up to 2.5% of the Russian hemostatic market, which is about 250 million rubles a year.

The attracted investments in the project will go to finalize the product, clinical trials, certification and launch of production. A year after the start, the payback may be 60%.

According to Alexander Maslennikov, managing partner of Mendeleev Venture Investments, the Sanguis team has demonstrated strong competencies in science and a deep understanding of the target market.

While working in the acceleration program, the project team has entered a new market niche for its product - medical products for veterinary medicine, which creates good opportunities to form an additional financial flow, while the base product will undergo the necessary clinical trials. We see great potential for Sanguis not only in Russia, but also in export markets. Despite the large number of alternative hemostatics, effective and inexpensive drugs are sorely lacking around the world, he said.